- Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filingCompass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…Endpoints · 20d ago↗ source
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsThe GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…Endpoints · 20d ago↗ source
- STAT+: Compass says depression drug has long-lasting benefitsVertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout